Arvinas Inc Net Income per Employee (ARVN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Arvinas Inc   (NASDAQ: ARVN)
 

Arvinas Inc Net Income per Employee

ARVN's Quarterly Results, Trends, Rankings, Statistics
Arvinas Inc recorded a cumulative net loss of $-10 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 206 other companies achieving higher income per employee. While Arvinas Inc 's total ranking has deteriorated compared to the previous quarter from 3643 to 3715.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARVN Net Income per Employee (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -38,618 37,805 -899,594 -328,455 -237,805
ARVN's Total Ranking # 3715 # 3643 # 0 # 2736 #
Seq. Net Income Change - - - - -

ARVN Company Profile >> Back to ARVN Efficiency Comparisons >> Compare ARVN Net Income per Employee to its Competitors

ARVN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 207
Healthcare Sector # 574
Overall Market # 3715

Net Income per Employee Statistics
High Average Low
$ 37,805 $ -667,767 $ -1,971,138
(Jun 30 2026)   (Sep 30 2023)




  News about Arvinas Inc Income per employee

Vepdegestrant A Promising Step Forward in Targeted Therapy for ER+/HER2- Breast Cancer

The landscape of breast cancer therapy is profoundly evolving, particularly with the emergence of innovative treatments targeting estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Arvinas, Inc. in collaboration with Pfizer, is at the forefront of this transformation with their investigational drug, vepdegestrant. In light of several significant presentations at prominent oncology conferences, we delve into the latest updates on vepdegestrant, assessing its clinical implications and potential impact on both patient outcomes and the strategic positioning of Arvinas within the oncology market. Key Facts about Vepdegestrant and Recent Developments 1. Investigational Drug Overview : - Vepdegestrant is classified as a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader. This novel mechanism facilitates the targeted degradation of the ER, aiming to provide enhanced treatment for patients suffering from ER+/HER2- breast cancer an aggressive subset of the disease.




Companies with similar Income per Employee for 12 month ending Sep 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2026Number of Employees Sep 30 2026


Date modified: 2026-11-04T15:06:30+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.